Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC)
Vogel, A. Chen, L. T. He, A. R. Kim, J. W. Chen, M. H. McNamara, Mairead G Shimizu, S. Gillmore, R. Rey, F. Kim, H.
Vogel, A.
Chen, L. T.
He, A. R.
Kim, J. W.
Chen, M. H.
McNamara, Mairead G
Shimizu, S.
Gillmore, R.
Rey, F.
Kim, H.
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Vogel A, Chen LT, He AR, Kim JW, Chen MH, McNamara MG, et al. Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC). Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301241.